Prognostic Implication and Functional Annotations of APOBEC3G Expression in Patients with Melanoma

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Aug 4

PMID 32742470

Citations 4

Authors

Wei Han

Jun Xu

Guo-Liang Shen

Affiliations

Soon will be listed here.

Abstract

Skin cutaneous melanoma (SKCM) is one of the most life-threatening malignancies damaging human health. APOBEC3G (A3G) has been found in several cancers; however, the role of A3G in SKCM is rarely studied. This study aimed to investigate the expression of A3G in tumor tissue and its prognostic value in SKCM patients. A total of 512 SKCM patients from the First Affiliated Hospital of Soochow University (FAHSU) and the Cancer Genome Atlas (TCGA) database were consecutively recruited in analyses. Differential transcriptional and proteome expression profiles were obtained from multiple datasets. GEPIA was used to assess the survival analysis between distinguished groups. Both univariate and multivariate Cox regression analysis was performed to address the influence of independent factors on disease-free survival (RFS) and overall survival (OS). In addition, 31 SKCM and 31 nevus tissues were collected for immunohistochemical (IHC) staining and evaluation. STRING, DAVID and Gene Set Enrichment Analysis (GSEA) was utilized to conduct a network of related genes and significant pathways. Furthermore, we investigated the relationship of A3G with tumor-infiltrating immune cells (TIICs) by TIMER and TISIDB. We found both transcriptional and proteomics expressions of A3G were elevated in SKCM. Survival analysis and ROC curves showed significant diagnostic and prognostic ability of A3G. IHC results showed increased expression of A3G in SKCM compared to nevus tissues. Importantly, A3G expression was closely associated with the immune-infiltrating levels of B cells, CD4+ T, CD8+ T, neutrophils, macrophages and dendritic cells. In summary, our study first reveals that elevated A3G expression is significantly correlated with better prognosis in SKCM patients. The role of A3G in SKCM demonstrated that it might be a prognostic and immunotherapeutic biomarker for SKCM.

Citing Articles

Comprehensive characterisation of immunogenic cell death in melanoma revealing the association with prognosis and tumor immune microenvironment.

Ren J, Yang J, Na S, Wang Y, Zhang L, Wang J Front Immunol. 2022; 13:998653.

PMID: 36211436 PMC: 9538190. DOI: 10.3389/fimmu.2022.998653.

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer.

Olah C, Reis H, Hoffmann M, Mairinger F, Ting S, Hadaschik B Cancer Med. 2022; 12(5):5222-5232.

PMID: 36204983 PMC: 10028049. DOI: 10.1002/cam4.5324.

The Identification of APOBEC3G as a Potential Prognostic Biomarker in Acute Myeloid Leukemia and a Possible Drug Target for Crotonoside.

Ma C, Liu P, Cui S, Gao C, Tan X, Liu Z Molecules. 2022; 27(18).

PMID: 36144542 PMC: 9503540. DOI: 10.3390/molecules27185804.

Prognostic Value and Immunological Characteristics of a Novel RNA Binding Protein Signature in Cutaneous Melanoma.

Tian J, Ma C, Yang L, Sun Y, Zhang Y Front Genet. 2021; 12:723796.

PMID: 34531901 PMC: 8438157. DOI: 10.3389/fgene.2021.723796.

References

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M . Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012; 490(7420):412-6. DOI: 10.1038/nature11538. View

Singh R, Mishra M, Aggarwal H . Inflammation, Immunity, and Cancer. Mediators Inflamm. 2017; 2017:6027305. PMC: 5695028. DOI: 10.1155/2017/6027305. View

Harris R, Liddament M . Retroviral restriction by APOBEC proteins. Nat Rev Immunol. 2004; 4(11):868-77. DOI: 10.1038/nri1489. View

Goodson A, Grossman D . Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol. 2009; 60(5):719-35. PMC: 2690513. DOI: 10.1016/j.jaad.2008.10.065. View

Karin M, Greten F . NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005; 5(10):749-59. DOI: 10.1038/nri1703. View

Johnson D, OKeefe R, Grandis J . Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018; 15(4):234-248. PMC: 5858971. DOI: 10.1038/nrclinonc.2018.8. View

Benci J, Xu B, Qiu Y, Wu T, Dada H, Twyman-Saint Victor C . Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell. 2016; 167(6):1540-1554.e12. PMC: 5385895. DOI: 10.1016/j.cell.2016.11.022. View

Fang S, Xu T, Xiong M, Zhou X, Wang Y, Haydu L . Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. J Invest Dermatol. 2019; 139(11):2352-2358.e3. PMC: 6814532. DOI: 10.1016/j.jid.2019.03.1158. View

10.

Litvin O, Schwartz S, Wan Z, Schild T, Rocco M, Oh N . Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma. Mol Cell. 2015; 57(5):784-796. PMC: 4355234. DOI: 10.1016/j.molcel.2014.12.030. View

11.

Iizuka T, Wakae K, Nakamura M, Kitamura K, Ono M, Fujiwara H . APOBEC3G is increasingly expressed on the human uterine cervical intraepithelial neoplasia along with disease progression. Am J Reprod Immunol. 2017; 78(4). DOI: 10.1111/aji.12703. View

12.

Di Trolio R, Simeone E, Di Lorenzo G, Buonerba C, Ascierto P . The use of interferon in melanoma patients: a systematic review. Cytokine Growth Factor Rev. 2014; 26(2):203-12. DOI: 10.1016/j.cytogfr.2014.11.008. View

13.

He X, Xu H, Wang X, He X, Niu J, Gao P . Association between polymorphisms of the gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2017; 23(2):232-241. PMC: 5236503. DOI: 10.3748/wjg.v23.i2.232. View

14.

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

15.

Sim G, Radvanyi L . The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014; 25(4):377-90. DOI: 10.1016/j.cytogfr.2014.07.018. View

16.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

17.

Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q . STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer. J Breast Cancer. 2013; 16(1):40-9. PMC: 3625768. DOI: 10.4048/jbc.2013.16.1.40. View

18.

Macha M, Matta A, Kaur J, Chauhan S, Thakar A, Shukla N . Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck. 2010; 33(4):482-9. DOI: 10.1002/hed.21468. View

19.

Na Y, Lee J, Lee S, Seok S . Interleukin-6-induced Twist and N-cadherin enhance melanoma cell metastasis. Melanoma Res. 2013; 23(6):434-43. DOI: 10.1097/CMR.0000000000000021. View

20.

Kushiro K, Chu R, Verma A, Nunez N . Adipocytes Promote B16BL6 Melanoma Cell Invasion and the Epithelial-to-Mesenchymal Transition. Cancer Microenviron. 2011; 5(1):73-82. PMC: 3343194. DOI: 10.1007/s12307-011-0087-2. View